Abstract
To predict the clinical efficacy of a new antibiotic in uncomplicated gonorrhea, data pertinent to its pharmacokinetics in man are needed. Before starting clinical trials of cefotiam and cefmenoxime, 1 g of each antibiotic was administrated i.m. as single dose to 5 healthy volunteers. Both blood and skin blister fluid samples (obtained by suction and cantharides blistering) were repeatedly taken. Peak plasma levels amounted on average to 24.8 and 48.2 .mu.g/ml, respectively. Six h after the dose, average plasma concentrations of 3.4 and 6.52 .mu.g/ml were found. Suction blister fluid levels essentially paralleled plasma levels, whereas cantharides blister fluid levels increased and decreased more slowly than plasma levels. Cefotiam penetrated more readily into suction blister fluid than cefmenoxime as obtained from area ratios. The chosen dosage regimens considered apt for gonorrhea led to high initial as well as long-standing drug levels. This does not only hold true for the plasma. Good in vitro activity on Neisseria gonorrhoeae indicate that cefotiam and cefmenoxime deserve further studies in this field, including clinical trials.